GSK plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Luke Victor Miels
- Full Time Employees
- 66,841
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 79 New Oxford Street London GL United Kingdom WC1A 1DG
- IPO Date
- May 22, 1972
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc operates as a global biopharmaceutical leader, dedicated to the research, development, and delivery of innovative medicines and vaccines across international markets. The company, which traces its origins back to 1715, refocused its strategy in July 2022 by spinning off its Consumer Healthcare division to form Haleon plc, thereby concentrating exclusively on its biopharma pipeline. Its operations are structured around key product areas: Specialty Medicines, Vaccines, and General Medicines. Within Specialty Medicines, GSK develops treatments for significant health challenges including HIV, oncology, respiratory conditions, and immuno-inflammatory diseases such as lupus. The Vaccines portfolio encompasses a broad range, preventing illnesses like shingles (Shingrix), meningitis, and respiratory syncytial virus (RSV) with its Arexvy vaccine. General Medicines typically address primary care needs, including inhalers for asthma and COPD, and various antibiotics. GSK generates revenue through the sale of these prescription products and vaccines to healthcare providers, hospitals, pharmacies, and governmental bodies worldwide. The company is strategically prioritizing investment in its innovative pipeline, anticipating at least twelve major product launches from 2025 in areas like infectious diseases, HIV, oncology, and respiratory health, reinforcing its commitment to scientific advancement. Recent corporate activities include strategic acquisitions such as Tesaro to bolster its oncology presence, and alliances with partners like CureVac for mRNA vaccine development. Headquartered in Brentford, United Kingdom, GSK aims to positively impact the health of 2.5 billion people by the end of the decade, driven by its purpose to unite science, technology, and talent to get ahead of disease. The company was formerly known as GlaxoSmithKline plc and adopted its current name, GSK plc, in May 2022.
Company News
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
HP taps Emma Walmsley, ex-GSK chief and Microsoft board member, as CEO
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK plc (GSK) Q3 2026 Earnings Call Transcript
What GSK (GSK) Said on Its Q3 Earnings Call
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
GSK: Why I'm Still Bullish After Strong Q3 Results
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
GSK Sales Get Boost From Specialty Medicines
GSK beats third-quarter profit estimates, keeps annual targets
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update
GSK to nearly double cancer drugs in trials, WSJ reports
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for